Janet L Clark

US Patent:

20060275761, Dec 7, 2006

Filed:

Sep 15, 2003

Appl. No.:

10/528309

Inventors:

Janet Clark - Matawan NJ, US
Susan Rohrer - Scotch Plains NJ, US
Stephen Alves - New York NY, US

International Classification:

C12Q 1/68

US Classification:

435006000

Abstract:

The present invention relates to methods of evaluation and detection of the expression of tryptophan hydroxylase (TPH) gene and induction of TPH by estrogen receptor-beta (ERβ) agonists, utilizing TPH riboprobe and/or primers.

US Patent:

20070274916, Nov 29, 2007

Filed:

Oct 20, 2004

Appl. No.:

10/576807

Inventors:

Janet Clark - Matawan NJ, US

International Classification:

A61K 49/00
C12Q 1/68
A61K 31/573

US Classification:

424009200, 435006000, 514171000

Abstract:

A method for identifying analytes which directly or indirectly affect tryptophan hydroxylase isoform 2 (TPH2) expression is described. The method enables glucocorticoid receptor modulators and &bgr;-hydroxysteroid dehydrogenase type 1 (&bgr,-HSD1) inhibitors to be screened for central nervous system penetrance and activity by determining their ability to regulate expression of TPH2. The method is particularly useful for identifying analytes which suppress glucocorticoid disruption of central serotonergic neurotransmission in the brain.

US Patent:

20080032959, Feb 7, 2008

Filed:

Jun 17, 2005

Appl. No.:

11/629317

Inventors:

Stephen Alves - New York NY, US
Janet Clark - Matawan NJ, US
Susan Rohrer - Scotch Plains NJ, US

International Classification:

A61K 31/56
A61P 1/02
A61P 1/06
A61P 19/10
A61P 25/24
A61P 25/28
A61P 27/02
A61P 5/30
A61P 5/32
A61P 9/00
A61P 9/12

US Classification:

514171000

Abstract:

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget's disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, anxiety, depression resulting from an estrogen deficiency, inflammation, inflammatory bowel disease, sexual dysfunction, hypertension, retinal degeneration and cancer, in particular of the breast, uterus and prostate.